Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiwan Biomateiral CoROCO:6649 80 Debt-to-EBITDA is 2.53 as of Jun. 2026, which is 267% above its 10-year median of 0.69. GuruFocus rates ROCO:6649 with a GF Score™ of 80/100 and a GF Value™ of NT$58.77 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Taiwan Biomateiral Co ranks better than 59.02% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Taiwan Biomateiral Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:6649'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.25 Med: 0.69 Max: 6.25
Current: 1.03
During the past 13 years, the highest Debt-to-EBITDA Ratio of Taiwan Biomateiral Co was 6.25. The lowest was -2.25. And the median was 0.69.
ROCO:6649's Debt-to-EBITDA is ranked better than 59.02% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs ROCO:6649: 1.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Taiwan Biomateiral Co Debt-to-EBITDA Related Terms
Taiwan Biomateiral Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Taiwan Biomateiral Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6649 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Taiwan Biomateiral Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Biomateiral Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Biomateiral Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Taiwan Biomateiral Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Taiwan Biomateiral Co (ROCO:6649) has a Debt-to-EBITDA of 2.53 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Taiwan Biomateiral Co. This is 267% above median its historical median of 0.69. According to the industry distribution chart, Taiwan Biomateiral Co ranks #193 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 41%.
Is Taiwan Biomateiral Co's Debt-to-EBITDA too high?
Taiwan Biomateiral Co's current Debt-to-EBITDA of 2.53 is 267% above median its 10-year median of 0.69. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Taiwan Biomateiral Co's value of 2.53 is 55.2% above this industry median. Based on the distribution chart, Taiwan Biomateiral Co ranks #193 out of 471 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Taiwan Biomateiral Co has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Biomateiral Co's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Taiwan Biomateiral Co ranks #193 out of 471 companies for Debt-to-EBITDA. This puts Taiwan Biomateiral Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.63. Taiwan Biomateiral Co's value of 2.53 is 55.2% above this benchmark. While the company's 10-year median is 0.69 vs. the industry median of 1.63, Taiwan Biomateiral Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Biomateiral Co's current Debt-to-EBITDA of 2.53 is 55.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Taiwan Biomateiral Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Biomateiral Co's current Debt-to-EBITDA is 2.53, which is 267% above median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Biomateiral Co stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Biomateiral Co (ROCO:6649) is currently considered Possible Value Trap. The stock's GF Value™ is NT$58.77, compared to a current price of NT$35.75 — trading 39.2% below its estimated fair value. The current Debt-to-EBITDA is 2.53, which is 267% above median its 10-year median of 0.69 and 55.2% above the Medical Devices & Instruments industry median of 1.63. Taiwan Biomateiral Co's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Taiwan Biomateiral Co (ROCO:6649), the current Debt-to-EBITDA is 2.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Biomateiral Co (ROCO:6649) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Biomateiral Co stock appears to be undervalued.
The current stock price of NT$35.75 is trading 39.2% below its estimated GF Value™ of NT$58.77.
GuruFocus considers Taiwan Biomateiral Co to be Possible Value Trap.
Key valuation signals for ROCO:6649:
Debt-to-EBITDA: 2.53 (267% above median its 10-year median of 0.69)
GF Value™: NT$58.77 vs. price of NT$35.75 (39.2% below fair value)
Industry Position: 55.2% above the Medical Devices & Instruments median (#193 of 471)
No single metric tells the full story. See the ROCO:6649 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Biomateiral Co Ltd is an applied technology Research and Development Institute in Taiwan. It is engaged in the research and development and sales of implantable medical devices. The company's products include Foamagen, stroke interventional treatment devices.
80GF Score
Get the complete analysis for ROCO:6649
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6649 has been successfully added to your 
